The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 15, 2021

Study Completion Date

April 15, 2022

Conditions
Type I Diabetes
Interventions
DRUG

Placebo GABA and Placebo GAD-alum

Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection

DRUG

GABA and Placebo GAD-alum

Oral Active GABA with Placebo GAD-alum

DRUG

Active Oral GABA and Active GAD-alum injection

Active Oral GABA and Active GAD-alum injection

Trial Locations (1)

35233

Children's of Alabama, Birmingham

All Listed Sponsors
collaborator

Diamyd Inc

INDUSTRY

collaborator

NOW Foods

OTHER

collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

University of Alabama at Birmingham

OTHER